News

The licensing rights of Raxone to Chiesi Group will be applicable in all countries with the exception of the US and Canada and in LHON and all other

Inheris will be responsible for launch preparation and commercialization for NKTR-181, a novel, first-in-class, investigational opioid molecule. NKTR-181 is currently under review with the U.S. Food and Drug

This revolutionary platform empowers scientists in the pharmaceutical industry to generate novel drug-like compounds by combining powerful methods for molecule generation, ADMET prediction, and high-throughput ligand-protein interaction prediction.

SORILUX is now approved for treating plaque psoriasis of the scalp and body in patients aged 12 years and older. The FDA approved SORILUX in 2010 based on

Based in Copenhagen, Nuevolution shares its advanced discovery platform and programmes with pharmaceutical and biotechnology companies to develop novel medical treatment options for the patients. Amgen’s offer represents

QVM149 is a combination of indacaterol acetate, glycopyrronium bromide and mometasone furoate, which was delivered with the dose-confirming BreezhalerIGB gas pipeline inhalation device during the mid-stage trials. The

WuXi Vaccines is a joint venture company to be established between WuXi Biologics and Shanghai based Hile Bio-Technology (stock code 603718.SH). The business model of WuXi Vaccines is

Under the deal, Merck’s subsidiary will purchase all outstanding shares of Peloton in exchange for an upfront payment of $1.05bn (£825m) in cash. The shareholders of Peloton will

Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The